Biodesix Targets 2028 Launch for Imaging-Based Lung Nodule Risk Test

Bitget2026/10/19 10:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Biodesix added digital diagnostics to its lung testing strategy, targeting a 2028 commercial launch for its first imaging-based lung nodule risk test.
Developed with Vanderbilt University and Vanderbilt Health, the test aims to improve lung cancer risk assessment alongside the Nodify Lung blood-testing portfolio.
Initial performance results will be presented at the RSNA annual meeting on December 3, 2026.
The prospective STRATIFY study is expected to begin in the fourth quarter of 2026, matching blood and imaging biomarkers with clinical outcomes.
The study will support clinical validation, reimbursement evidence and future multimodal diagnostic development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190600PRIMZONEFULLFEED9848106) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Biodesix Targets 2028 Launch for Imaging-Based Lung Nodule Risk Test

You may also like

Crypto prices